Mehdi Ahmadi Sabegh* and Jabbar Khalafy

The regioselective catalyst-free synthesis of bis-quinoxalines and bis-pyrido[2,3-b]pyrazines by double condensation of 1,4-phenylene-bis-glyoxal with 1,2-diamines

https://doi.org/10.1515/hc-2018-0039 Received March 17, 2018; accepted May 18, 2018

Abstract: The oxidation of 1,4-diacetylbenzene using several oxidizing agents gave 1,4-phenylene-bis-glyoxal in 61–85% yields. A convenient and efficient synthesis of bis-quinoxaline and bis-pyrido[2,3-*b*]pyrazine derivatives involves the double condensation of 1,2-diamines with 1,4-phenylene-bis-glyoxal in ethanol under reflux conditions. The structures of the new products were defined by proton nuclear magnetic resonance (¹H NMR), carbon-13 nuclear magnetic resonance (¹³C NMR), Fourier-transform infrared spectroscopy (FT-IR) and mass spectrometry (MS).

Keywords: 1,2-diamines; 1,4-phenylene-bis-glyoxal; bis-pyrido[2,3-*b*]pyrazines bis-quinoxalines; regioselectivity; selenium dioxide.

Introduction

Glyoxals are important building blocks in organic synthesis, particularly in the synthesis of biologically active heterocyclic compounds [1–9] including quinoxaline derivatives [10–26]. Synthesis of a quinoxaline by the reaction of a glyoxal with a 1,2-diamine is part of the general strategy involving the reaction of 1,2-dicarbonyl compounds with 1,2-diamines [27–30]. In continuation of our studies on the development of new synthetic routes to heterocyclic compounds using arylglyoxals, herein we report the synthesis of new bis-quinoxaline derivatives **3a-f** in a 68–94% yield via condensation of 1,4-phenylene-bis-glyoxal as its hydrate **1** (structure in Scheme 1) and 1,2-diamines **2a-f** in ethanol under reflux conditions.

Results and discussion

The glyoxal hydrate **1** was synthesized by oxidation of 1,4-diacetylbenzene using different oxidizing agents in a 61-85% yield. The SeO₂/dioxane/H₂O system is preferred to other oxidizing agents as its use provides product **1** in an 85% yield after crystallization from water. The use of other oxidizing systems described in the literature, namely HBr/DMSO/H₂O, CuCl₂/DMSO/H₂O and I₂/CuO/DMSO, furnished compound **1** in the respective yields of 73%, 65% and 61%.

The condensation of compound **1** with 1,2-diamines **2a–f** in ethanol under reflux gave the desired bis-quinoxalines and bis-pyrido[2,3-*b*]pyrazines under catalyst-free conditions in a 68–89% yield (Scheme 1). The use of unsymmetrical aromatic diamines **2b**, **2e** and **2f** could in principle lead to isomeric products, but the formation of a single product in each case shows that the reactions are regioselective. As can be seen, in the condensation of bis-glyoxal **1** with 4-nitro-1,2-diaminobenzene (**2b**) and



Scheme 1

*Corresponding author: Mehdi Ahmadi Sabegh, Department of Organic Chemistry, Faculty of Chemistry, Urmia University, Urmia 57154, Iran, e-mail: mahmadis88@yahoo.com, m-ahmadi@iau-ahar.ac.ir Jabbar Khalafy: Department of Organic Chemistry, Faculty of Chemistry, Urmia University, Urmia 57154, Iran aminopyridines **2e** or **2f**, the more nucleophilic 1-amino group attacks the formyl group in the first step, and the condensation of the less reactive 2-amino group with the keto groups occurs in the second step, leading to the formation of bis-quinoxaline **3b**. The reactions of aminopyridines **2e** and **2f** with **1** follow a similar pattern and furnish regioselectively the respective bis-pyrido[2,3-*b*]pyrazines **3e** and **3f**. This reactivity pattern is in full agreement with previous mechanistic studies on the construction of fused pyrazines [27–30].

Conclusion

A double condensation of 1,4-phenylene-bis-glyoxal with various 1,2-diamines furnished bis-quinoxaline derivatives 3a-f in high to excellent yields. The simplicity of operation, high yields and regioselectivity are the key advantages of this method.

Experimental

Melting points were measured on an Electrothermal 9200 apparatus and are uncorrected. Infrared spectra were measured on a Spectrum RXI, Perkin Elmer, UK Fourier-transform infrared (FT-IR) instrument using KBr disks. The ¹H (300 MHz) and ¹³C (75 MHz) nuclear magnetic resonance (NMR) spectra were recorded on a Bruker DRX-300 Avance spectrometer in DMSO-*d*₆, CDCl₃ and C₆D₆ relative to tetramethylsilane (TMS) as the internal reference. Thin layer chromatography (TLC) was carried out on a pre-coated aluminum sheet with silica gel 60F 254 obtained from Merck, and detection was made with the help of an ultraviolet (UV) lamp (λ 254 nm). Mass analysis was performed on an Agilent Technology (HP) 5973 Network Mass Selective Detector and high-resolution mass spectra were recorded on a Kratos mass spectrometry (MS) 25RF spectrometer.

Synthesis of 1,1'-(1,4-phenylene)bis(2,2-dihydroxyethanone) (1)

A solution of selenium dioxide (1.55 g, 14 mmol) in 90% aqueous dioxane (10 mL) was treated at 100°C with a solution of 1,4-diacetylbenzene (1.62 g, 10 mmol) in dioxane (12 mL). The mixture was heated under reflux for 14 h and the precipitated selenium was removed by filtration. The solution was cooled and the resultant pale yellow precipitate of product 1 was collected and crystallized from water: yield 1.92 g (85%); mp 141–142°C; IR: v_{max} 3428, 3377, 2975, 1670, 1505, 1446, 1407, 1297, 1121, 1037, 962, 873, 801, 696, 584, 517 cm⁻¹; ¹H NMR (DMSO- d_o): δ 8.15 (s, 4H), 6.90 (d, J = 7.2 Hz, 4H, 4 × OH, exchanged by D₂O addition), 5.68 (bt, J = 7.2 Hz, 2H, changed to a singlet after D₂O addition); ¹³C NMR (DMSO- d_o): δ 196.5, 137.4, 129.7, 89.9; MS: m/z (%) 226 ([M]⁺, 59), 184 (100), 163 (58), 149 (65), 133 (76), 105 (59), 91 (52), 77 (56), 55 (75). ESI-HRMS: Calcd. for C₁₀H₁₀O₆, [M]⁺: m/z 226.0477. Found: m/z 226.0462.

General procedure for the synthesis of bis-quinoxalines and bis-pyrido[2,3-*b*]pyrazines (3a–f)

A mixture of 1,4-phenylene-bis-glyoxal (1, 1 mmol) and a 1,2-diamine (**2a–f**, 2 mmol) in absolute ethanol (10 mL) was heated under reflux for 10–15 h, then cooled and the resultant precipitate of **3a–f** was filtered, washed with ethanol and crystallized from ethanol.

1,4-Bis-(quinoxalin-2-yl)benzene (3a) Reaction time 12 h; yield 82% of light yellow powder; mp 264–266°C; IR: ν_{max} 3054, 1678, 1609, 1574, 1545, 1490, 1462, 1426, 1370, 1320, 1262, 1231, 1208, 1130, 1054, 1014, 956, 847, 756, 674, 630, 601, 566 cm⁻¹; ¹H NMR (CDCl₃): δ 9.45 (s, 2H), 8.45 (s, 4H), 8.24–8.16 (m, 4H), 7.85–7.80 (m, 4H); ¹³C NMR (CDCl₃): δ 150.9, 142.4, 141.8, 138.3, 130.5, 129.9, 129.7, 129.2, 128.2; EI-MS: *m/z* (%) 335 ([M+1]⁺, 28), 334 [M]⁺ (100), 307 (11), 306 (17), 204 (12), 76 (19). ESI-HRMS. Calcd. for C₂₂H₁₄N₄, [M]⁺: 334.1218. Found: *m/z* 334.1205.

1,4-Bis(6-nitroquinoxalin-2-yl)benzene (3b) Reaction time 15 h; yield 68% of orange powder; mp 235–236°C; IR: v_{max} 3047, 1578, 1554, 1348, 1320, 1280, 1193, 1078, 1050, 964, 844, 831, 792, 742 cm⁻¹; ¹H NMR (C₆D₆): δ 9.16 (s, 1H), 9.13 (s, 1H), 8.20 (s, 4H), 8.10 (d, *J* = 9 Hz, 2H), 798 (d, *J* = 9 Hz, 2H), 710 (bs, 2H); ¹³C NMR (C₆D₆): δ 138.5, 137.7, 136.1, 135.7, 133.7, 127.6, 126.9, 124.6, 124.0, 123.8; EI-MS: *m/z* (%) 425 ([M+1]⁺, 27), 424 ([M]⁺, 100), 394 (25), 382 (11), 351 (14), 75 (13). ESI-HRMS. Calcd. for C₂,H₁,N₆O₆, [M]⁺: *m/z* 424.0920. Found: *m/z* 424.0907.

1,4-Bis(6-methoxyquinolin-2-yl)benzene (3c) Reaction time 10 h; yield 89% of brown powder; mp 267–268°C; IR: v_{max} 3047, 1616, 1498, 1374, 1321, 1261, 1217, 1201, 1173, 1122, 1060, 1026, 958, 846, 830, 779 cm⁻¹; 'H NMR (DMSO- d_6): δ 9.52 (s, 2H), 8.55(s, 4H), 8.03 (d, J = 8.7 Hz, 2H), 7.54 (s, 2H), 7.51 (d, J = 8.7 Hz, 2H), 3.86 (s, 6H); ¹³C NMR spectrum could not be recorded due to low solubility of the sample; EI-MS: m/z (%) 395 ([M+1]⁺, 29), 394 ([M]⁺, 100), 262 (10), 197 (7), 106 (12), 63 (10). ESI-HRMS. Calcd. for C₂₄H₁₈N₄O₂, [M]⁺: m/z 394.1430. Found: m/z 394.1416.

1,4-Bis(6,7-dichloroquinoxalin-2-yl)benzene (3d) Reaction time 12 h; yield 78% of gray powder; mp 190–191°C; the ¹H NMR and ¹³C NMR spectra could not be recorded due to low solubility of the sample; IR: v_{max} 3066, 3045, 1544, 1459, 1418, 1317, 1274, 1177, 1111, 1058, 1016, 945, 928, 900, 878, 840, 810, 660, 624 cm⁻¹; EI-MS: m/z (%) 478 ([M+6]⁺, 14), 474 ([M+4]⁺, 52), 472 ([M+2]⁺, 100), 470 ([M]⁺, 80), 300 (17), 272 (15), 237 (11), 170 (13), 146 (32), 144 (50), 109 (30), 74 (12). ESI-HRMS. Calcd. for $C_{22}H_{10}Cl_4N_4$, [M]⁺: m/z 469.9660. Found: m/z 469.9648.

1,4-Bis(pyrido[2,3-*b***]pyrazine-2-yl)benzene (3e)** Reaction time 10 h; yield 80% of brown powder; mp 320–321°C; IR: v_{max} 3413, 3067, 2372, 1546, 1461, 1310, 209, 1125, 1061, 952, 848, 794 cm⁻¹; ¹H NMR (CDCl₃): δ 9.29 (s, 2H), 9.25 (bs, 2H) 8.82 (s, 4H), 8.54 (d, *J*=7.8 Hz, 2H), 7.77 (dd, *J*₁=8.4 Hz, *J*₂=4.5 Hz, 2H); ¹³C NMR spectrum could not be recorded due to low solubility of the sample; EI-MS: *m/z* (%) 337 ([M+1]⁺, 24), 336 ([M]⁺, 100), 308 (9), 233 (20), 205 (9), 104 (10), 77 (14). ESI-HRMS. Calcd. for C₂₀H₁, *N_e*, [M]⁺ *m/z* 336.1123. Found: *m/z* 336.1111.

1,4-Bis(pyrido[3,4-b]pyrazine-2-yl)benzene (3f) Reaction time 10 h; yield 78% of creamy powder; mp 248–249°C; IR: ν_{max} 3216, 2373, 1547, 1419, 1317, 1235, 1054, 960, 854, 837, 584 cm⁻¹; ¹H NMR (CDCl₂): δ 9.62 (s, 2H), 9.55 (s, 2H), 8.90 (d, J=5.7 Hz, 2H), 8.52 (s, 4H), 8.04 (d, J=6 Hz, 2H); ¹³C NMR (CDCl₃+DMSO- d_6): δ 154.2, 147.7, 145.2, 144.8, 136.8, 128.9, 128.5, 121.9, 121.5; EI-MS: m/z (%) 337 ([M+1]⁺, 22), 336 ([M]⁺, 100), 309 (13), 308 (15), 233 (11), 77 (11), 50 (32). ESI-HRMS. Calcd. for C₂₀H₂₀N₆, [M]⁺: m/z 336.1123. Found: m/z 336.111.

Acknowledgments: We are grateful to Urmia University for the financial support and we also thank Professor R. H. Prager (Flinders University, Australia) for language editing and proofreading of this article.

References

- Zaliani, V.; Cocconcelli, G.; Fantini, M.; Ghiron, C.; Rivara, M. A practical synthesis of 2,4(5)-diarylimidazoles from simple building blocks. *J. Org. Chem.* 2007, *72*, 4551–4553.
- [2] Juspin, T.; Terme, T.; Vanelle, P. Rapid access to diphenyl- and acenaphthoguinoline derivatives. *Synfacts* 2009, 9, 1485–1489.
- [3] Fischer, B.; Kabha, E.; Gendron, F. P.; Beaudoin, A. R. Analytical ancestry: "firsts" in fluorescent labeling of nucleosides, nucleotides, and nucleic acids. J. Med. Chem. 2000, 19, 1033–1034.
- [4] Prashanthukumar, B. R.; Sharma, G. K.; Srinath, S.; Noor, M.; Suresh, B.; Srinivasa, B. R. Synthesis and biological evaluation of newer benzofuran derivatives as potential anticancer and anathematic agents. *J. Heterocycl. Chem.* **2009**, *46*, 278.
- [5] Robjohn, N. Selenium dioxide oxidation. Org. React. 1949, 5, 331.
- [6] Robjohn, N. Selenium dioxide oxidation. Org. React. 1976, 24, 261.
- [7] Kornblum, N.; Powers, J. W.; Anderson, G. J.; Jones, W. J.; Larson, H. O.; Weaver, W. M. Conversion of aldehydes to amides via dimethyl sulfoxide oxidation of the corresponding α-aminonitriles. J. Am. Chem. Soc. 1957, 79, 6562.
- [8] Schaefer, J. P. Selenium dioxide oxidations. I. studies on the mechanism of oxidation of 1,2-dibenzoylethane. J. Am. Chem. Soc. 1962, 84, 713–716.
- [9] Zhiling, C.; Dahua, Sh.; Ying, Q.; Chuanzhou, T.; Weiwei, L.; Guowei, Y. A new method for synthesis of 3,6-diacetyl-9-ethylcarbazole and its oxidation to the corresponding diglyoxal using several oxidizing agents. *Molecules* 2013, 18, 15717–15723.
- [10] Zarranz, B.; Jaso, A.; Aldana, I.; Monge, A. Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethylquinoxaline 1,4-di-*N*-oxide derivatives. *J. Med. Chem.* 2004, *12*, 3711–3721.
- [11] Grande, F.; Aiello, F.; Grazia, O. D.; Brizzi, A.; Garofalo, A.; Neamati, N. Synthesis and antitumor activities of a series of novel quinoxalin hydrazides. *J. Med. Chem.* 2005, 15, 288–294.
- [12] Ali, M. M.; Ismail, M. M. F.; El-Gaby, M. S. A.; Zahran, M. A.; Ammar, T. A. Synthesis and anti-microbial activity of some novel quinoxaline derivatives. *Molecules* **2000**, *5*, 864–873.
- [13] Seitz, L. E.; Suling, W. J.; Reynolds, R. C. Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives. *J. Med. Chem.* 2002, 45, 5604–5606.

- [14] Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as antimycobacterium tuberculosis agents. *J. Med. Chem.* 2005, 48, 2019–2025.
- [15] Bailly, C.; Echepare, S.; Gago, F.; Waring, M. Recognition elements that determine affinity and sequence-specific binding to DNA of 2QN, a biosynthetic bis-quinoline analogue of echinomycin. J. Med. Chem. 1999, 14, 291–303.
- [16] Gomtsyan, A.; Bayburt, E. K.; Schmidt, R. G.; Zheng, G. Z.; Perner, R. J.; Didomenico, S.; Koeni, J. R.; Turner, S.; Jinkerson, T.; Drizin, I.; et al. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structureactivity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. J. Med. Chem. 2005, 48, 744–752.
- [17] Perumal, R. V.; Mahesh, R. Synthesis and biological evaluation of a novel structural type of serotonin 5-HT3 receptor antagonists. *Bioorg. Med. Chem. Lett.* 2006, *16*, 2769–2772.
- [18] Tandon, V. K.; Yadav, D. B.; Maurya, H. K., Chaturvedi, A. K.; Shukla, P. K. Design, synthesis, and biological evaluation of 1,2,3-trisubstituted-1,4-dihydrobenzo[g]quinoxaline-5,10-diones and related compounds as antifungal and antibacterial agents. J. Med. Chem. 2006, 14, 6120–6126.
- [19] Carta, A.; Loriga, M.; Paglietti, G.; Mattana, A.; Fiori, P. L.; Mollicotti, P.; Echi, L.; Zanetti, S. Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline-1,4-dioxides. *J. Med. Chem.* **2004**, *39*, 195–203.
- [20] Mashevskaya, I.; Makhmudov, R. R.; Aleksandrova, G. A.; Golovnira, O. V.; Duvalov, A. V.; Maslivets, A. N. Synthesis and study of the antibacterial and analgesic activity of 3-acyl-1,2,4,5-tetrahydro-[1,2-*a*]quinoxaline-1,2,4-triones. *Pharm. Chem. J.* **2001**, *35*, 196–198.
- [21] Vyas, D. A.; Chauhan, N. A.; Parikh, A. R. Synthesis and antimicrobial activity of quinoxaline based thiazolidinones and azetidinones. *Indian J. Chem.* 2007, 46B, 1699–1702.
- [22] Burguete, A.; Pontiki, E.; Litina, D. H.; Villar, R.; Vicente, E.; Solano, B.; Ancizu, S.; Aldana, I.; Monge, A. Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-*N*-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1*H*)-pyrazole analogues. *Bioorg. Med. Chem. Lett.* 2007, *17*, 6439–6443.
- [23] Wagle, S.; Adhikari, A. V.; Kumari, N. S. Synthesis of some new 2-(3-methyl-7-substituted-2-oxoquinoxalinyl)-5-(aryl)-1,3,4oxadiazoles as potential nonsteroidal anti-inflammatory and analgesic agents. *Indian J. Chem.* 2008, 47B, 439–448.
- [24] Kim, Y. B.; Kim, Y. H.; Park, J. Y.; Kim, S. K. Synthesis and biological activity of new quinoxaline antibiotics of echinomycin analogues. *Bioorg. Med. Chem. Lett.* 2004, 14, 541–544.
- [25] Palanaki, M. S. S.; Dneprovskaia, E.; Doukas, J.; Fine, R. M.; Hood, J.; Kang, X.; Lohse, D.; Martin, M.; Noronha, G.; Soll, R. M.; et al. Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl) diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. J. Med. Chem. 2007, 50, 4279–4294.
- [26] Bandyopadhayay, D.; Cruz, J.; Morales, D. L.; Arman, H.; Cuate, E.; Lee, Y. S.; Banik, B. K.; Kim, D. An expeditious green route toward 2-aryl-4-phenyl-1*H*-imidazoles. *J. Med. Chem.* 2013, *5*, 1377.

- [27] Sako, M. Methods of Molecular Transformations. In Science of Synthesis. Yamamoto, Y., Ed. Houben-Weyl Thieme: Stuttgart, New York, 2003; Vol. 16, pp 1269–1290.
- [28] Brown, D. J. A Series of Monographs; Quinoxalines: Supplement
 II. In *The Chemistry of Heterocyclic Compounds*. Taylor, E. C.,
 Wipf, P., Eds. John Wiley & Sons: New Jersey, 2004; Vol. 61.
- [29] Porter, A. E. A. Quinoxalines. In *Comprehensive Heterocyclic Chemistry A*. Katritsky, R., Rees, C. W., Eds. Oxford: Pergamum, 1984; p 157.
- [30] Khalafy, J.; Poursattar Marjani, A.; Haghipour, M. Regioselective synthesis of 3-arylpyrido[2,3-*b*]pyrazines by reaction of arylgly-oxals with 2,3-diaminopyridine. *Curr. Chem. Lett.* **2013**, *2*, 21–26.